Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Listed as NCT00002924, this observational or N/A phase trial focuses on Prostate Cancer and remains completed. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 11 times since 1997, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jan 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States, Birmingham, United States, Boston, United States, Buffalo, United States, Chapel Hill, United States, Charleston, United States, Chicago, United States, Columbia, United States, Columbus, United States, Durham, United States and 23 more location s